10 20 30 40 50 60 70 80 1WCO - Header ----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----| Asymmetric UnitHEADER PEPTIDE/ANTIBIOTIC 19-NOV-04 1WCO
TITLE THE SOLUTION STRUCTURE OF THE NISIN-LIPID II COMPLEX
COMPND MOL_ID: 1; COMPND 2 MOLECULE: NISIN Z; COMPND 3 CHAIN: N; COMPND 4 MOL_ID: 2; COMPND 5 MOLECULE: NAG-MUB-ALA-FGA-LYS-DAL-DAL PEPTIDE; COMPND 6 CHAIN: L
SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: LACTOCOCCUS LACTIS; SOURCE 3 ORGANISM_TAXID: 1358; SOURCE 4 STRAIN: NIZO 22186; SOURCE 5 MOL_ID: 2; SOURCE 6 ORGANISM_SCIENTIFIC: MONARTHROPALPUS FLAVUS; SOURCE 7 ORGANISM_TAXID: 71816
KEYWDS PEPTIDE-ANTIBIOTIC COMPLEX, LANTIBIOTIC, ANTIMICROBIAL, BACTERIOCIN, KEYWDS 2 THIOESTER, PORE FORMATION, PYROPHOSPHATE CAGE, FOOD PRESERVATIVE
EXPDTA SOLUTION NMR
NUMMDL 20
AUTHOR S.-T.D.HSU,E.BREUKINK,E.TISCHENKO,M.A.G.LUTTERS,B.DE KRUIJFF, AUTHOR 2 R.KAPTEIN,A.M.J.J.BONVIN,N.A.J.VAN NULAND
REVDAT 6 13-JUL-11 1WCO 1 VERSN REVDAT 5 24-FEB-09 1WCO 1 VERSN REVDAT 4 15-MAY-07 1WCO 1 REMARK SEQRES MODRES HET REVDAT 4 2 HETNAM HETSYN FORMUL LINK REVDAT 4 3 HETATM TER ENDMDL MODEL REVDAT 4 4 CONECT REVDAT 3 01-MAR-06 1WCO 1 HETATM REVDAT 2 14-MAR-05 1WCO 1 SPRSDE REVDAT 1 07-MAR-05 1WCO 0
SPRSDE 07-MAR-05 1WCO 1UZT
JRNL AUTH S.-T.D.HSU,E.BREUKINK,E.TISCHENKO,M.A.G.LUTTERS, JRNL AUTH 2 B.DE KRUIJFF,R.KAPTEIN,A.M.J.J.BONVIN,N.A.J.VAN NULAND JRNL TITL THE NISIN-LIPID II COMPLEX REVEALS A PYROPHOSPHATE CAGE JRNL TITL 2 THAT PROVIDES A BLUEPRINT FOR NOVEL ANTIBIOTICS JRNL REF NAT.STRUCT.MOL.BIOL. V. 11 963 2004 JRNL REFN ISSN 1545-9993 JRNL PMID 15361862 JRNL DOI 10.1038/NSMB830
REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH S.-T.D.HSU,E.BREUKINK,B.DE KRUIJFF,R.KAPTEIN,A.M.J.J.BONVIN, REMARK 1 AUTH 2 N.A.J.VAN NULAND REMARK 1 TITL MAPPING THE TARGETED MEMBRANE PORE FORMATION MECHANISM BY REMARK 1 TITL 2 SOLUTION NMR: THE NISIN Z AND LIPID II INTERACTION IN SDS REMARK 1 TITL 3 MICELLES REMARK 1 REF BIOCHEMISTRY V. 41 7670 2002 REMARK 1 REFN ISSN 0006-2960 REMARK 1 PMID 12056898 REMARK 1 DOI 10.1021/BI025679T REMARK 1 REFERENCE 2 REMARK 1 AUTH E.BREUKINK,I.WIEDEMANN,C.VAN KRAAIJ,O.P.KUIPERS,H.G.SAHL, REMARK 1 AUTH 2 B.DE KRUIJFF REMARK 1 TITL USE OF THE CELL WALL PRECURSOR LIPID II BY A PORE- FORMING REMARK 1 TITL 2 PEPTIDE ANTIBIOTIC REMARK 1 REF SCIENCE V. 286 2361 1999 REMARK 1 REFN ISSN 0036-8075 REMARK 1 PMID 10600751 REMARK 1 DOI 10.1126/SCIENCE.286.5448.2361 REMARK 1 REFERENCE 3 REMARK 1 AUTH J.LINGE,M.A.WILLIAMS,C.A.E.M.SPRONK,A.M.J.J.BONVIN,M.NILGES REMARK 1 TITL REFINEMENT OF PROTEIN STRUCTURES IN EXPLICIT SOLVENT REMARK 1 REF PROTEINS: STRUCT.,FUNCT., V. 50 496 2003 REMARK 1 REF 2 GENET. REMARK 1 REFN ISSN 0887-3585 REMARK 1 PMID 12557191 REMARK 1 DOI 10.1002/PROT.10299 REMARK 1 REFERENCE 4 REMARK 1 AUTH C.DOMINGUEZ,R.BOELENS,A.M.J.J.BONVIN REMARK 1 TITL HADDOCK: A PROTEIN-PROTEIN DOCKING APPROACH BASED ON REMARK 1 TITL 2 BIOCHEMICAL OR BIOPHYSICAL INFORMATION REMARK 1 REF J.AM.CHEM.SOC. V. 125 1731 2003 REMARK 1 REFN ISSN 0002-7863 REMARK 1 PMID 12580598 REMARK 1 DOI 10.1021/JA026939X
REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE.
REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS, GROSSE- REMARK 3 KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU,READ, REMARK 3 RICE,SIMONSON,WARREN REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REFINEMENT DETAILS CAN BE FOUND IN REMARK 3 THE JRNL CITATION ABOVE. THE ENSEMBLE OF STRUCTURES IS REMARK 3 SUPERIMPOSED ON THE CA OF NISIN RESIDUES 1-12 (CHAIN N), REMARK 3 THE HEAVY ATOMS OF MURNAC, PYROPHOSPHATE AND THE FIRST REMARK 3 ISOPRENE OF 3-LIPID II (CHAIN L) AS THESE ARE THE ONLY REMARK 3 SEGMENTS THAT HAVE SUFFICIENT DISTANCE RESTRAINTS TO DEFINE REMARK 3 THE COMPLEX STRUCTURE. OTHER RESIDUES NAMELY RESIDUES 13-34 REMARK 3 (ESPECIALLY RESIDUES 20-34) OF NISIN, THE PENTAPEPTIDE AND REMARK 3 TERMINAL ISOPRENE UNITS OF 3-LIPID II ARE FLEXIBLE AS REMARK 3 SUPPORTED BY DYNAMICS DATA. THE ATOM OCCUPANCY OF THE C- REMARK 3 TERMINAL TAIL OF NISIN (RESIDUES 20-34) HAS BEEN MODIFIED TO REMARK 3 BE 0.3 TO REFLECT THEIR DISORDER/FLEXIBILITY.
REMARK 4 REMARK 4 1WCO COMPLIES WITH FORMAT V. 3.30, 13-JUL-11
REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 23-NOV-04. REMARK 100 THE PDBE ID CODE IS EBI-21726.
REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 300.0 REMARK 210 PH : NULL REMARK 210 IONIC STRENGTH : NULL REMARK 210 PRESSURE : 1.0 REMARK 210 SAMPLE CONTENTS : 100% D6-DMSO REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 1H-15N CT HSQC; 31P 1D ; REMARK 210 1H-13C HSQC; 1H-13C HMBC; REMARK 210 31P 1D ; 1H-15N-NOESY HSQC; REMARK 210 1H-1H NOESY; 1H-15N TOCSY- REMARK 210 HSQC;1H-1H TOCSY; 1H-1H REMARK 210 COSY ; 1H-15N-NOESY HSQC; REMARK 210 1H-1H NOESY REMARK 210 SPECTROMETER FIELD STRENGTH : 500 ; 600 ; 750 ; REMARK 210 900 REMARK 210 SPECTROMETER MODEL : AVANCE REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : NMR VIEW AND CNS REMARK 210 METHOD USED : HADDOCK REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 200 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 20 REMARK 210 CONFORMERS, SELECTION CRITERIA : RMSD CLUSTERING AND LOWEST REMARK 210 TOTAL ENERGY REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : NULL REMARK 210 REMARK 210 REMARK: THE STRUCTURE WAS DETERMINED USING MULTIDIMENSIONAL REMARK 210 NMR SPECTROSCOPY ON 15N-LABELLED NISIN IN COMPLEX WITH REMARK 210 UNLABELLED 3-LIPID II. INTERMOLECULAR HYDROGEN BONDS WERE REMARK 210 IDENTIFIED AND USED IN STRUCTURAL CALCULATION BY 31P- REMARK 210 EDITED 1H-15N CT HSQC.
REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS.
REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA.
REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1840 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 3510 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -2.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: L, N REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 400 REMARK 400 COMPOUND REMARK 400 NISIN Z IS A LANTIBIOTIC. THE LANTIBIOTICS REMARK 400 ARE CHARACTERIZED BY LANTHIONINE AND/OR METHYLLANTHIONINE REMARK 400 NONPROTEINOGENIC AMINO ACIDS. REMARK 400 HERE, NISIN Z IS REPRESENTED BY THE SEQUENCE (SEQRES) REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: NISIN Z REMARK 400 CHAIN: N REMARK 400 COMPONENT_1: PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 34 REMARK 400 DESCRIPTION: NISIN Z IS A PENTACYCLIC PEPTIDE. THIOETHER BONDS REMARK 400 WITH CYSTEINE RESULT IN FIVE CYCLIC STRUCTURES ALONG REMARK 400 THE PEPTIDE CHAIN. REMARK 400 CROSSLINK 3-7 METHYLLANTHIONINE (DAL-CYS) REMARK 400 CROSSLINK 8-11 BETA-METHYLLANTHIONINE (DBB-CYS) REMARK 400 CROSSLINK 13-19 BETA-METHYLLANTHIONINE (DBB-CYS) REMARK 400 CROSSLINK 23-26 BETA-METHYLLANTHIONINE (DBB-CYS) REMARK 400 CROSSLINK 25-28 BETA-METHYLLANTHIONINE (DBB-CYS)
REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 DBB N 8 -58.97 147.76 REMARK 500 1 LYS N 12 1.93 -151.30 REMARK 500 1 MET N 17 -46.71 -154.38 REMARK 500 1 CYS N 19 82.90 63.18 REMARK 500 1 ASN N 20 -81.18 -57.88 REMARK 500 1 HIS N 31 -82.45 -126.21 REMARK 500 2 DAL L 6 -73.98 -71.81 REMARK 500 2 DBB N 13 46.61 -73.72 REMARK 500 2 MET N 17 -33.77 -160.00 REMARK 500 2 CYS N 19 91.33 65.39 REMARK 500 2 MET N 21 39.53 73.82 REMARK 500 3 DAL L 6 21.26 -74.60 REMARK 500 3 DBB N 8 -53.57 150.47 REMARK 500 3 DBB N 13 46.83 -73.72 REMARK 500 3 MET N 17 -30.53 -138.14 REMARK 500 3 CYS N 19 79.16 60.11 REMARK 500 3 ASN N 20 -80.10 -68.09 REMARK 500 3 MET N 21 -31.16 75.27 REMARK 500 3 DBB N 23 38.88 174.54 REMARK 500 3 ALA N 24 74.54 -117.37 REMARK 500 3 ILE N 30 55.63 -90.11 REMARK 500 4 DAL L 6 -82.63 -178.22 REMARK 500 4 LEU N 6 68.85 -101.79 REMARK 500 4 CYS N 7 99.10 -63.52 REMARK 500 4 DBB N 8 -57.27 150.92 REMARK 500 4 DBB N 13 44.97 -73.79 REMARK 500 4 MET N 17 -36.02 -150.61 REMARK 500 4 CYS N 19 87.97 70.22 REMARK 500 4 MET N 21 -49.92 74.53 REMARK 500 5 DAL L 6 40.04 145.50 REMARK 500 5 DBB N 8 -53.07 153.14 REMARK 500 5 DBB N 13 25.69 -81.60 REMARK 500 5 MET N 17 -57.69 -149.99 REMARK 500 5 CYS N 19 70.83 65.63 REMARK 500 5 ASN N 20 -81.51 70.51 REMARK 500 6 DAL L 6 46.55 -75.27 REMARK 500 6 CYS N 7 90.44 -59.40 REMARK 500 6 DBB N 8 -54.95 150.13 REMARK 500 6 DBB N 13 32.70 -73.93 REMARK 500 6 MET N 17 -42.41 -152.97 REMARK 500 6 ASN N 20 -23.20 174.42 REMARK 500 6 ILE N 30 32.34 -91.79 REMARK 500 7 DAL L 6 -37.64 170.25 REMARK 500 7 CYS N 7 99.45 -59.99 REMARK 500 7 DBB N 8 -53.50 146.75 REMARK 500 7 DBB N 13 52.35 -70.51 REMARK 500 7 MET N 17 -58.47 -136.07 REMARK 500 7 CYS N 19 177.59 64.80 REMARK 500 7 ASN N 20 -71.63 -119.19 REMARK 500 7 MET N 21 -47.13 73.57 REMARK 500 REMARK 500 THIS ENTRY HAS 129 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL
REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 MUB L 2
REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE FPP N 35 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN N OF NISIN Z REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR CHAIN L OF REMARK 800 NAG-MUB-ALA-FGA-LYS-DAL-DAL PEPTIDE
REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1AJ1 RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE LANTIBIOTIC ACTAGARDINE REMARK 900 RELATED ID: 1MQX RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF TYPE B LANTIBIOTICS MERSACIDIN IN REMARK 900 MEOH/H2O MIXTURE REMARK 900 RELATED ID: 1MQY RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF TYPE B LANTIBIOTICS MERSACIDIN IN REMARK 900 DPC MICELLES REMARK 900 RELATED ID: 1MQZ RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF TYPE B LANTIBIOTICS MERSACIDIN REMARK 900 BOUND TO LIPID II IN DPC MICELLES REMARK 900 RELATED ID: 1QOW RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE TUPE B LANTIBIOTIC MERSACIDIN REMARK 900 RELATED ID: 1W9N RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE LANTIBIOTIC EPILANCIN 15X REMARK 900 RELATED ID: 2DDE RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE LANTIBIOTIC CINNAMYCIN COMPLEXED REMARK 900 WITH LYSOPHOSPHATIDYLETHANOLAMINE REMARK 900 RELATED ID: 2KTN RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF LCH-ALPHA PEPTIDE FROM TWO-COMPONENT REMARK 900 LANTIBIOTIC SYSTEM LICHENICIDIN VK21 A1 REMARK 900 RELATED ID: 2KTO RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF LCH-BETA PEPTIDE FROM TWO-COMPONENT REMARK 900 LANTIBIOTIC LICHENICIDIN VK21 A2
DBREF 1WCO L 1 7 PDB 1WCO 1WCO 1 7 DBREF 1WCO N 1 34 UNP P29559 LANZ_LACLA 24 57
SEQRES 1 L 7 NAG MUB ALA FGA LYS DAL DAL SEQRES 1 N 34 ILE DBU DAL ILE DHA LEU CYS DBB PRO GLY CYS LYS DBB SEQRES 2 N 34 GLY ALA LEU MET GLY CYS ASN MET LYS DBB ALA DBB CYS SEQRES 3 N 34 ASN CYS SER ILE HIS VAL DHA LYS
MODRES 1WCO DBU N 2 THR POST-TRANSLATIONAL MODIFICATION MODRES 1WCO DAL N 3 SER POST-TRANSLATIONAL MODIFICATION MODRES 1WCO DHA N 5 SER POST-TRANSLATIONAL MODIFICATION MODRES 1WCO DBB N 8 THR POST-TRANSLATIONAL MODIFICATION MODRES 1WCO DBB N 13 THR POST-TRANSLATIONAL MODIFICATION MODRES 1WCO DBB N 23 THR POST-TRANSLATIONAL MODIFICATION MODRES 1WCO DBB N 25 THR POST-TRANSLATIONAL MODIFICATION MODRES 1WCO DHA N 33 SER POST-TRANSLATIONAL MODIFICATION
HET NAG L 1 28 HET MUB L 2 35 HET FGA L 4 15 HET DAL L 6 10 HET DAL L 7 11 HET DBU N 2 11 HET DAL N 3 9 HET DHA N 5 8 HET DBB N 8 12 HET DBB N 13 12 HET DBB N 23 12 HET DBB N 25 12 HET DHA N 33 8 HET FPP N 35 48
HETNAM FGA D-GAMMA GLUTAMIC ACID HETNAM DAL D-ALANINE HETNAM DBU (2E)-2-AMINOBUT-2-ENOIC ACID HETNAM DHA 2-AMINO-ACRYLIC ACID HETNAM DBB D-ALPHA-AMINOBUTYRIC ACID HETNAM NAG N-ACETYL-D-GLUCOSAMINE HETNAM MUB N-ACETYLMURAMIC ACID HETNAM FPP FARNESYL DIPHOSPHATE
HETSYN FGA D-GLUTAMIC ACID HETSYN DBU Z-DEHYDROBUTYRINE HETSYN DHA 2,3-DIDEHYDROALANINE
FORMUL 1 FGA C5 H9 N O4 FORMUL 1 DAL 3(C3 H7 N O2) FORMUL 2 DBU C4 H7 N O2 FORMUL 2 DHA 2(C3 H5 N O2) FORMUL 2 DBB 4(C4 H9 N O2) FORMUL 3 NAG C8 H15 N O6 FORMUL 4 MUB C11 H19 N O8 FORMUL 5 FPP C15 H28 O7 P2
HELIX 1 1 DBB N 8 DBB N 13 1 6
LINK C1 NAG L 1 O4 MUB L 2 1555 1555 1.42 LINK C10 MUB L 2 N ALA L 3 1555 1555 1.33 LINK C ALA L 3 N FGA L 4 1555 1555 1.32 LINK CD FGA L 4 N LYS L 5 1555 1555 1.32 LINK C LYS L 5 N DAL L 6 1555 1555 1.33 LINK C DAL L 6 N DAL L 7 1555 1555 1.34 LINK C ILE N 1 N DBU N 2 1555 1555 1.34 LINK C DBU N 2 N DAL N 3 1555 1555 1.32 LINK CB DAL N 3 SG CYS N 7 1555 1555 1.79 LINK C DAL N 3 N ILE N 4 1555 1555 1.32 LINK C ILE N 4 N DHA N 5 1555 1555 1.34 LINK C DHA N 5 N LEU N 6 1555 1555 1.32 LINK C CYS N 7 N DBB N 8 1555 1555 1.32 LINK CB DBB N 8 SG CYS N 11 1555 1555 1.81 LINK C DBB N 8 N PRO N 9 1555 1555 1.35 LINK C LYS N 12 N DBB N 13 1555 1555 1.33 LINK CB DBB N 13 SG CYS N 19 1555 1555 1.83 LINK C DBB N 13 N GLY N 14 1555 1555 1.33 LINK C LYS N 22 N DBB N 23 1555 1555 1.32 LINK CB DBB N 23 SG CYS N 26 1555 1555 1.82 LINK C DBB N 23 N ALA N 24 1555 1555 1.33 LINK C ALA N 24 N DBB N 25 1555 1555 1.32 LINK CB DBB N 25 SG CYS N 28 1555 1555 1.82 LINK C DBB N 25 N CYS N 26 1555 1555 1.32 LINK C VAL N 32 N DHA N 33 1555 1555 1.33 LINK C DHA N 33 N LYS N 34 1555 1555 1.32 LINK PB FPP N 35 O1 MUB L 2 1555 1555 1.60
SITE 1 AC1 11 MUB L 2 ILE N 1 DBU N 2 DAL N 3 SITE 2 AC1 11 ILE N 4 DHA N 5 LEU N 6 CYS N 7 SITE 3 AC1 11 DBB N 8 PRO N 9 GLY N 10 SITE 1 AC2 6 MUB L 2 ALA L 3 FGA L 4 DAL L 6 SITE 2 AC2 6 DAL L 7 FPP N 35 SITE 1 AC3 7 ILE N 1 DBU N 2 ILE N 4 GLY N 10 SITE 2 AC3 7 DBB N 13 GLY N 14 FPP N 35
CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 1.000000 0.000000 0.000000 0.00000
SCALE2 0.000000 1.000000 0.000000 0.00000
SCALE3 0.000000 0.000000 1.000000 0.00000